References
Key articles
Ortonne J-P. Vitiligo and other disorders of hypopigmentation. In: Bolognia JL, Jorrizzo JL, Rapini RP, eds. Dermatology. New York, NY: Mosby; 2008:913-38.
Taieb A, Picardo M. Clinical practice: vitiligo. N Engl J Med. 2009 Jan 8;360(2):160-9. Abstract
Taieb A, Alomar A, Böhm M, et al; Vitiligo European Task Force (VETF); European Academy of Dermatology and Venereology (EADV); Union Européenne des Médecins Spécialistes (UEMS). Guidelines for the management of vitiligo: the European Dermatology Forum consensus. Br J Dermatol. 2013 Jan;168(1):5-19.Full text Abstract
Whitton ME, Pinart M, Batchelor J, et al. Interventions for vitiligo. Cochrane Database Syst Rev. 2015 Feb 24;(2):CD003263.Full text Abstract
Reference articles
1. Ezzedine K, Lim HW, Suzuki T, et al. Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res. 2012 May;25(3):E1-13.Full text Abstract
2. Halder RM, Taliaferro SJ. Vitiligo. In: Wolff K, Goldsmith LA, Katz SI, et al., eds. Fitzpatrick's dermatology in general medicine. New York, NY: McGraw-Hill; 2008:616-22.
3. Dupré A, Christol B. Cockade-like vitiligo and linear vitiligo a variant of fitzpatrick's trichrome vitiligo. Arch Dermatol Res. 1978 Jul 28;262(2):197-203. Abstract
4. Ortonne J-P. Vitiligo and other disorders of hypopigmentation. In: Bolognia JL, Jorrizzo JL, Rapini RP, eds. Dermatology. New York, NY: Mosby; 2008:913-38.
5. Sosa JJ, Currimbhoy SD, Ukoha U, et al. Confetti-like depigmentation: a potential sign of rapidly progressing vitiligo. J Am Acad Dermatol. 2015 Aug;73(2):272-5. Abstract
7. Gandhi K, Ezzedine K, Anastassopoulos KP, et al. Prevalence of vitiligo among adults in the United States. JAMA Dermatol. 2022 Jan 1;158(1):43-50.Full text Abstract
8. Shankar DS, Shashikala K, Madala R. Clinical patterns of vitiligo and its associated comorbidities: a prospective controlled cross-sectional study in South India. Indian Dermatol Online J. 2012 May;3(2):114-8.Full text Abstract
9. Majumder PP, Nordlund JJ, Nath SK. Pattern of familial aggregation of vitiligo. Arch Dermatol. 1993 Aug;129(8):994-8. Abstract
10. Taieb A, Picardo M. Clinical practice: vitiligo. N Engl J Med. 2009 Jan 8;360(2):160-9. Abstract
11. Zhang Y, Cai Y, Shi M, et al. The prevalence of vitiligo: a meta-analysis. PLoS One. 2016 Sep 27;11(9):e0163806.Full text Abstract
12. Spritz RA, Santorico SA. The genetic basis of vitiligo. J Invest Dermatol. 2021 Feb;141(2):265-73. Abstract
13. Shen C, Gao J, Sheng Y, et al. Genetic susceptibility to vitiligo: GWAS approaches for identifying vitiligo susceptibility genes and loci. Front Genet. 2016 Feb 1;7:3.Full text Abstract
14. Alikhan A, Felsten LM, Daly M, et al. Vitiligo: a comprehensive overview. Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol. 2011 Sep;65(3):473-91. Abstract
15. van den Boorn JG, Konijnenberg D, Dellemijn TA, et al. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol. 2009 Sep;129(9):2220-32.Full text Abstract
16. Ogg GS, Rod Dunbar P, Romero P, et al. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med. 1998 Sep 21;188(6):1203-8.Full text Abstract
17. Passeron T, Ortonne JP. Activation of the unfolded protein response in vitiligo: the missing link? J Invest Dermatol. 2012 Nov;132(11):2502-4.Full text Abstract
18. Shah AA, Sinha AA. Oxidative stress and autoimmune skin disease. Eur J Dermatol. 2013 Jan-Feb;23(1):5-13. Abstract
19. Laddha NC, Dwivedi M, Mansuri MS, et al. Vitiligo: interplay between oxidative stress and immune system. Exp Dermatol. 2013 Apr;22(4):245-50.Full text Abstract
20. Toosi S, Orlow SJ, Manga P. Vitiligo-inducing phenols activate the unfolded protein response in melanocytes resulting in upregulation of IL6 and IL8. J Invest Dermatol. 2012 Nov;132(11):2601-9.Full text Abstract
21. Schallreuter KU, Bahadoran P, Picardo M, et al. Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else? Exp Dermatol. 2008 Feb;17(2):139-40.Full text Abstract
22. Richmond JM, Frisoli ML, Harris JE. Innate immune mechanisms in vitiligo: danger from within. Curr Opin Immunol. 2013 Dec;25(6):676-82.Full text Abstract
23. Mosenson JA, Zloza A, Klarquist J, et al. HSP70i is a critical component of the immune response leading to vitiligo. Pigment Cell Melanoma Res. 2012 Jan;25(1):88-98.Full text Abstract
24. Mosenson JA, Zloza A, Nieland JD, et al. Mutant HSP70 reverses autoimmune depigmentation in vitiligo. Sci Transl Med. 2013 Feb 27;5(174):174ra28.Full text Abstract
25. Wang Y, Li S, Li C. Perspectives of new advances in the pathogenesis of vitiligo: from oxidative stress to autoimmunity. Med Sci Monit. 2019 Feb 6;25:1017-23.Full text Abstract
26. Rashighi M, Agarwal P, Richmond JM, et al. CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Sci Transl Med. 2014 Feb 12;6(223):223ra23.Full text Abstract
27. Roberts GHL, Santorico SA, Spritz RA. The genetic architecture of vitiligo. Pigment Cell Melanoma Res. 2020 Jan;33(1):8-15.Full text Abstract
28. Roberts GHL, Santorico SA, Spritz RA. Deep genotype imputation captures virtually all heritability of autoimmune vitiligo. Hum Mol Genet. 2020 Mar 27;29(5):859-63.Full text Abstract
29. van den Boorn JG, Melief CJ, Luiten RM. Monobenzone-induced depigmentation: from enzymatic blockade to autoimmunity. Pigment Cell Melanoma Res. 2011 Aug;24(4):673-9. Abstract
30. Alkhateeb A, Fain PR, Thody A, et al. Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Res. 2003 Jun;16(3):208-14. Abstract
31. Barona MI, Arrunategui A, Falabella R, et al. An epidemiologic case-control study in a population with vitiligo. J Am Acad Dermatol. 1995 Oct;33(4):621-5. Abstract
33. Wu S, Li WQ, Cho E, et al. Use of permanent hair dyes and risk of vitiligo in women. Pigment Cell Melanoma Res. 2015 Nov;28(6):744-6. Abstract
34. Mason CP, Gawkrodger DJ. Vitiligo presentation in adults. Clin Exp Dermatol. 2005 Jul;30(4):344-5. Abstract
35. Narita T, Oiso N, Fukai K, et al. Generalized vitiligo and associated autoimmune diseases in Japanese patients and their families. Allergol Int. 2011 Dec;60(4):505-8.Full text Abstract
36. Sawicki J, Siddha S, Rosen C. Vitiligo and associated autoimmune disease: retrospective review of 300 patients. J Cutan Med Surg. 2012 Jul-Aug;16(4):261-6. Abstract
37. Wagoner MD, Albert DM, Lerner AB, et al. New observations on vitiligo and ocular disease. Am J Ophthalmol. 1983 Jul;96(1):16-26. Abstract
38. Kroon MW, Joore IC, Wind BS, et al. Low yield of routine screening for thyroid dysfunction in asymptomatic patients with vitiligo. Br J Dermatol. 2012 Mar;166(3):532-8. Abstract
39. Taieb A, Alomar A, Böhm M, et al; Vitiligo European Task Force (VETF); European Academy of Dermatology and Venereology (EADV); Union Européenne des Médecins Spécialistes (UEMS). Guidelines for the management of vitiligo: the European Dermatology Forum consensus. Br J Dermatol. 2013 Jan;168(1):5-19.Full text Abstract
40. Ongenae K, Beelaert L, van Geel N, et al. Psychosocial effects of vitiligo. J Eur Acad Dermatol Venereol. 2006 Jan;20(1):1-8. Abstract
41. Ezzedine K, Eleftheriadou V, Whitton M, et al. Vitiligo. Lancet. 2015 Jul 4;386(9988):74-84. Abstract
42. Eleftheriadou V, Atkar R, Batchelor J, et al. British Association of Dermatologists guidelines for the management of people with vitiligo 2021. Br J Dermatol. 2022 Jan;186(1):18-29.Full text Abstract
43. Suga Y, Ikejima A, Matsuba S, et al. Medical pearl: DHA application for camouflaging segmental vitiligo and piebald lesions. J Am Acad Dermatol. 2002 Sep;47(3):436-8. Abstract
44. Whitton ME, Pinart M, Batchelor J, et al. Interventions for vitiligo. Cochrane Database Syst Rev. 2015 Feb 24;(2):CD003263.Full text Abstract
45. Westerhof W, Nieuweboer-Krobotova L, Mulder PG, et al. Left-right comparison study of the combination of fluticasone propionate and UV-A vs. either fluticasone propionate or UV-A alone for the long-term treatment of vitiligo. Arch Dermatol. 1999 Sep;135(9):1061-6.Full text Abstract
46. Lee JH, Kwon HS, Jung HM, et al. Treatment outcomes of topical calcineurin inhibitor therapy for patients with vitiligo: a systematic review and meta-analysis. JAMA Dermatol. 2019 Aug 1;155(8):929-38.Full text Abstract
47. Lepe V, Moncada B, Castanedo-Cazares JP, et al. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol. 2003 May;139(5):581-5.Full text Abstract
48. Hofer A, Hassan AS, Legat FJ, et al. Optimal weekly frequency of 308-nm excimer laser treatment in vitiligo patients. Br J Dermatol. 2005 May;152(5):981-5. Abstract
49. Mavilia L, Mori M, Rossi R, et al. 308 nm monochromatic excimer light in dermatology: personal experience and review of the literature. G Ital Dermatol Venereol. 2008 Oct;143(5):329-37. Abstract
50. Ju HJ, Bae JM, Lee RW, et al. Surgical interventions for patients with vitiligo: a systematic review and meta-analysis. JAMA Dermatol. 2021 Mar 1;157(3):307-16. Abstract
51. Radakovic-Fijan S, Furnsinn-Friedl AM, Honigsmann H, et al. Oral dexamethasone pulse treatment for vitiligo. J Am Acad Dermatol. 2001 May;44(5):814-7. Abstract
52. Eleftheriadou V, Hamzavi I, Pandya AG, et al. International Initiative for Outcomes (INFO) for vitiligo: workshops with patients with vitiligo on repigmentation. Br J Dermatol. 2019 Mar;180(3):574-9. Abstract
53. Thissen M, Westerhof W. Laser treatment for further depigmentation in vitiligo. Int J Dermatol. 1997 May;36(5):386-8. Abstract
54. Njoo MD, Vodegel RM, Westerhof W. Depigmentation therapy in vitiligo universalis with topical 4-methoxyphenol and the Q-switched ruby laser. J Am Acad Dermatol. 2000 May;42(5 Pt 1):760-9. Abstract
55. Lim HW, Grimes PE, Agbai O, et al. Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. JAMA Dermatol. 2015;151:42-50.Full text Abstract
56. Toh JJH, Chuah SY, Jhingan A, et al. Afamelanotide implants and narrow-band ultraviolet B phototherapy for the treatment of nonsegmental vitiligo in Asians. J Am Acad Dermatol. 2020 Jun;82(6):1517-9.Full text Abstract
57. Rosmarin D, Pandya AG, Lebwohl M, et al. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial. Lancet. 2020 Jul 11;396(10244):110-20. Abstract
58. Gawkrodger DJ, Ormerod AD, Shaw L, et al. Guideline for the diagnosis and management of vitiligo. Br J Dermatol. 2008 Nov;159(5):1051-76. Abstract
59. Whitton ME, Ashcroft DM, Gonzalez U. Therapeutic interventions for vitiligo. J Am Acad Dermatol. 2008 Oct;59(4):713-7. Abstract
60. Njoo MD, Das PK, Bos JD, et al. Association of the Koebner phenomenon with disease activity and therapeutic responsiveness in vitiligo vulgaris. Arch Dermatol. 1999 Apr;135(4):407-13.Full text Abstract
61. Calanchini-Postizzi E, Frenk E. Long-term actinic damage in sun-exposed vitiligo and normally pigmented skin. Dermatologica. 1987;174(6):266-71. Abstract
62. Hexsel CL, Eide MJ, Johnson CC, et al. Incidence of nonmelanoma skin cancer in a cohort of patients with vitiligo. J Am Acad Dermatol. 2009 Jun;60(6):929-33.Full text Abstract
63. Schallreuter KU, Tobin DJ, Panske A. Decreased photodamage and low incidence of non-melanoma skin cancer in 136 sun-exposed caucasian patients with vitiligo. Dermatology. 2002;204(3):194-201. Abstract
64. Teulings HE, Overkamp M, Ceylan E, et al. Decreased risk of melanoma and nonmelanoma skin cancer in patients with vitiligo: a survey among 1307 patients and their partners. Br J Dermatol. 2013 Jan;168(1):162-71. Abstract
65. Paradisi A, Tabolli S, Didona B, et al. Markedly reduced incidence of melanoma and nonmelanoma skin cancer in a nonconcurrent cohort of 10,040 patients with vitiligo. J Am Acad Dermatol. 2014 Dec;71(6):1110-6. Abstract
66. Hong CK, Lee MH, Jeong KH, et al. Clinical analysis of hearing levels in vitiligo patients. Eur J Dermatol. 2009 Jan-Feb;19(1):50-6. Abstract
Use of this content is subject to our disclaimer